Quantcast
Last updated on April 17, 2014 at 11:16 EDT

Latest WuXi PharmaTech Stories

2014-04-15 08:30:39

SHANGHAI, April 15, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2013, with the Securities and Exchange Commission. The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section. WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of...

2014-04-15 08:29:25

Dr. Steve Yang Joins Company as EVP and Chief Operating Officer; Edward Hu Named Chief Investment Officer and Remains Chief Financial Officer SHANGHAI, April 15, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that Dr. Steve Yang has joined the company as Executive Vice President and Chief Operating Officer. Edward Hu will...

2014-04-08 08:32:08

SHANGHAI, April 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that it has received an honorable mention award at the International Society for Pharmaceutical Engineering's (ISPE) 2014 Facility of the Year Awards for the company's recently completed cGMP cell-culture-based biologics production facility in Wuxi. These...

2014-04-07 12:32:58

SHANGHAI, April 7, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, today announced that it has received an honorable mention award at the International Society for Pharmaceutical Engineering's (ISPE) 2014 Facility of the Year Awards for the company's recently completed cGMP cell-culture-based biologics production facility in Wuxi. These...

2014-04-01 08:28:33

SHANGHAI and HONOLULU, April 1, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, and TruTag Technologies, Inc., developer of the leading edible, covert security platform to address the global product counterfeiting challenge, today announced that WuXi Corporate Venture Fund has made an investment in TruTag. In addition, WuXi and TruTag will...

2014-03-11 08:29:38

SHANGHAI and SEATTLE, March 11, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, and Pacific Biomarkers (PBI), a premier biomarker laboratory services provider based in Seattle, today announced a biomarker collaboration. In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's...

2014-03-10 08:28:44

SAN DIEGO and SHANGHAI, March 10, 2014 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. This new investment will enable WuXi's clinical genomic services to expand from the current target panel, exome, and...

2014-03-05 16:26:25

SHANGHAI, March 5, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the fourth quarter and full year of 2013. Fourth-Quarter 2013 Highlights -- Net Revenues Increased 25.1% Year Over Year to $157.2 Million -- Laboratory Services Net Revenues Grew 15.1%...

2014-02-26 12:25:05

SHANGHAI, Feb. 26, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that Dr. Hua Mu has joined WuXi as Senior Vice President of Operations and Global Head of the Product Development Service and Partnership Business Unit, reporting to Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. Dr. Mu has over 18 years of clinical...

2014-02-10 08:26:21

SHANGHAI, Feb. 10, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the fourth quarter and full year of 2013 after the New York Stock Exchange closes on Wednesday, March 5, 2014 (which will be Thursday morning, March 6, 2014 Shanghai time). The earnings release will be available...